Jasper Therapeutics Announces Oral Presentation of Positive Final ... - Marketscreener.com
| JSPRW Stock | USD 0.22 0.01 4.76% |
Slightly above 56% of all Jasper Therapeutics' sophisticated investors are looking to take a long position. The analysis of the overall investor sentiment regarding Jasper Therapeutics suggests that some traders are interested. Jasper Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Jasper Therapeutics' earnings reports, geopolitical events, and overall market trends.
Jasper |
Jasper Therapeutics Announces Oral Presentation of Positive Final ... Marketscreener.com
Read at news.google.com
 |
Jasper Therapeutics Fundamental Analysis
We analyze Jasper Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jasper Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jasper Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Debt To Equity
Debt To Equity Comparative Analysis
Jasper Therapeutics is currently under evaluation in debt to equity category among its peers. Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Jasper Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Jasper Therapeutics stock to make a market-neutral strategy. Peer analysis of Jasper Therapeutics could also be used in its relative valuation, which is a method of valuing Jasper Therapeutics by comparing valuation metrics with similar companies.
Peers
Jasper Therapeutics Related Equities
| SCPH | Scpharmaceuticals | 5.57 | ||||
| MIST | Milestone Pharmaceuticals | 0.54 | ||||
| LUMO | Lumos Pharma | 0.47 | ||||
| MCRB | Seres Therapeutics | 1.12 | ||||
| ELYM | Eliem Therapeutics | 2.91 |
Additional Tools for Jasper Stock Analysis
When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.